Shorepower Technologies, Inc. acquires Aeternum Health LLC for USD 1,500,000 (2026)

Deal facts

Buyer: Shorepower Technologies, Inc.
Target: Aeternum Health LLC
Deal value: USD 1,500,000
Announced: 23 February 2026
Status: Firm intention
Sector: Healthcare
Country: United States
Consideration: shares, cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

23 Feb 2026Firm intention
Shorepower Technologies, Inc. firm intention to acquire Aeternum Health LLC
Item 2.01 Completion of Acquisition or Disposition of Assets. On February 17, 2026, the registrant, Shorepower Technologies, Inc. a Delaware corporation (“Shorepower” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Aeternum Health LLC, a Delaware limited liability company (“Aeternum Health”) under which Aeternum Health will be merged with and into Shore
Source

OpinionExit Mode editorial

We see a clear signal in the announced firm intention for Shorepower Technologies, Inc to acquire Aeternum Health LLC. This is a strategic move within the US healthcare sector, valued at 1.5 million USD. The deal structure mixes cash and shares, which tells us the buyer wants to balance immediate liquidity for the sellers with long-term alignment through equity. For the SME founder reading this, the choice of mixed consideration is often a negotiation lever. It allows you to secure some cash now while retaining a stake in the future upside of the combined entity.

The announcement date of 23 February 2026 places this transaction in a specific regulatory window. While both parties operate in the US, any cross-border elements or significant market share concentration would trigger scrutiny from the Federal Trade Commission or the Department of Justice. Even at this modest valuation, the change-of-control covenants in existing contracts could be activated. You must review every supplier and client agreement for clauses that require consent upon a sale. Ignoring these triggers can derail a deal that otherwise looks sound on paper. The mixed consideration also suggests the buyer may be managing its own cash flow or capital structure carefully, preferring to use its own stock to fund part of the purchase price.

We think the real test here is not the headline value but the mechanics of the earn-out or retention arrangements implied by the share component. When a deal is structured this way, the seller often faces performance contingencies tied to the new entity. If the target does not hit specific milestones, the share value could dilute or vanish. This is a concrete risk that founders must model before signing. Do not assume the 1.5 million USD figure is guaranteed cash in hand. The mix of payment methods creates a scenario where your final return depends on the operational success of the combined business post-close.

Your immediate task this week is to request a draft of the purchase agreement from your advisors and specifically isolate the sections detailing the share vesting schedule and the conditions for cash payment. Verify if there are any clawback provisions tied to the equity portion. Do not proceed until you understand exactly how the mixed consideration converts into real value for you over the next three years.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Shorepower Technologies, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history